Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 2, 2011, Pages 125-129

  Kim, Ji Won ^a   Lee, Jeong Ok ^a   Han, Sae Won ^a   Oh, Do Youn ^a,b   Im, Seock Ah ^a,b   Kim, Tae You ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Fluoropyrimidine; Hepatocellular carcinoma; Platinum; Sorafenib

Indexed keywords

FLUOROPYRIMIDINE; PLATINUM; SORAFENIB;

ADULT; AGED; ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CHRONIC HEPATITIS; CLINICAL ARTICLE; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MALE; METASTASIS; NAUSEA; NEUTROPENIA; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DEOXYCYTIDINE; DRUG TOXICITY; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 79955979815     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d31ed2     Document Type: Article

References (26)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2: 533-543. (Pubitemid 33586866)
2. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171. (Pubitemid 34454013)
3. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoem-bolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739. (Pubitemid 34607087)
4. Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299:1669-1677.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362:1907-1917. (Pubitemid 37518510)
6. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988;62:479-483.
7. Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:452-459. (Pubitemid 32397659)
8. Ikeda M, Okusaka T, Ueno H, et al. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer. 2005;103:756.
9. Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998;27:951-958. (Pubitemid 28160479)
10. Huynh H, Nguyen TT, Chow KH, et al. Over-expression of the mitogenactivated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.
11. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130:1117-1128.
12. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41:864-880. (Pubitemid 39434320)
13. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
14. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851-11858. (Pubitemid 46094197)
15. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma. Hepatology. 2003;37:429-442. (Pubitemid 36152543)
16. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
17. Cheng AL, Kang YK, Chen Z, et al. Efflcacy and safety of sorafenib in patients in the Asia-Paciflc region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
19. Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer. 2006;6:3.
20. Ikeda M, Okusaka T, Ueno H, et al. Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. Jpn J Clin Oncol. 2008;38:675-682.
21. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-4300. (Pubitemid 46630787)
22. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115:428-436.
23. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer. 1989;64:1700-1707. (Pubitemid 19251142)
24. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classiflcation for predicting survival in patients with hepatocellular carcinoma: groupe d'etude et de traitement du carcinome hepatocellulaire. J Hepatol. 1999;31:133-141. (Pubitemid 29287619)
25. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27:446-452.
26. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia paciflc region. J Gastroenterol Hepatol. 2009;24:346-353.